Beijing Hotgen Biotech Co., Ltd. (SHA:688068)

China · Delayed Price · Currency is CNY

107.80

+4.69 (4.55%)

Jul 31, 2026, 3:00 PM CST

Beijing Hotgen Biotech Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	427.66	404.88	509.78	547.84	3,557	5,369
Revenue Growth	-12.16%	-20.58%	-6.95%	-84.60%	-33.76%	945.54%
Gross Profit	247.31	225.28	253.84	336.11	1,790	3,116
Operating Income	-306.73	-274.23	-211.74	-45.55	1,095	2,574
Net Income	-246.7	-216.05	-205.77	28.92	944.74	2,186
Earnings Per Share	-2.68	-2.36	-2.36	0.33	10.28	23.75
EPS Growth	-	-	-	-96.81%	-56.72%	1852.80%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Overseas	21.96
China	373.5
Total	395.46

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	1,213	1,367	1,085	606.13	1,463	2,089
Total Debt	3.84	50.49	42.9	15.26	42.13	35.98
Net Cash (Debt)	1,209	1,317	1,042	590.87	1,421	2,053
Net Cash Growth	3.25%	26.39%	76.31%	-58.42%	-30.77%	436.43%
Net Cash Per Share	13.16	14.38	11.95	6.69	15.46	22.30

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-133.94	-83.36	-90.16	-48.53	978.75	2,644
Capital Expenditures	-55.92	-43.57	-52.82	-413.37	-565.21	-398.86
Free Cash Flow	-189.86	-126.93	-142.98	-461.9	413.54	2,246
Free Cash Flow Growth	-	-	-	-	-81.58%	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	57.83%	55.64%	49.79%	61.35%	50.34%	58.03%
Operating Margin	-71.72%	-67.73%	-41.53%	-8.31%	30.79%	47.93%
Pretax Margin	-71.73%	-66.01%	-44.22%	2.74%	30.23%	48.09%
Profit Margin	-57.69%	-53.36%	-40.36%	5.28%	26.56%	40.71%
FCF Margin	-44.40%	-31.35%	-28.05%	-84.31%	11.63%	41.82%

Dividends

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.200	-	3.378
Dividend Per Share Growth	-	-	233.34%
Dividend Yield	0.49%	-	4.51%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	126.90	5.93	3.31
Forward PE	-	228.67	135.17	33.40	33.40	33.40
P/FCF Ratio	-	-	-	-	13.56	3.22
PS Ratio	22.18	35.54	10.87	6.70	1.58	1.35